Please wait while the formulary information is being retrieved.
ESTROGEN-METHYLTESTOSTERONE (ESTROGENS,ESTERIFIED/METHYLTESTOSTERONE)
- Esterified Estrogens-methyltestosterone Tablet
- Eemt Tablet
- Eemt Hs Tablet
- Covaryx Tablet
- Covaryx H.s. Tablet
- By Indication
esterified 0.625 mg-1.25 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
esterified 1.25 mg-2.5 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
esterified estrogens-methyltestosterone 0.625 mg-1.25 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
esterified estrogens-methyltestosterone 1.25 mg-2.5 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
1.25 mg-2.5 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
EEMT HS 0.625 mg-1.25 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
1.25 mg-2.5 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
0.625 mg-1.25 mg tablet
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
Vasomotor symptoms associated with menopause
- 1 tablet by oral route for 21 consecutive days, followed by 7 days off
- 2 tablets by oral route once daily for 21 consecutive days, followed by 7 days off
- anastrozole
- Arimidex
- Aromasin
- exemestane
- Femara
- letrozole
Contraindicated
- Coumadin
- cyclosporine
- cyclosporine modified
- Gengraf
- Jantoven
- Neoral
- Sandimmune
- warfarin
Severe
Moderate
- A-hydrocort
- A-methapred
- Alagesic Lq
- amobarbital
- Amytal
- Anucort-hc
- Anusol-hc
- Aristospan Intra-articular
- Aristospan Intralesional
- Ascomp With Codeine
- Belladonna-phenobarbital
- betamethasone acet & sod phos
- Bivigam
- Brevital
- budesonide
- Bupap
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- Carimune Nf Nanofiltered
- Celestone Soluspan
- Cerebyx
- codeine-butalbital-ASA-caff
- Colocort
- Cortef
- Cortenema
- Cortifoam
- cortisone
- Depo-medrol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Entocort Ec
- Esgic
- ethotoin
- Evista
- Ez Use Joint-tunnel-trigger
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- First-duke's
- First-mary's Mouthwash
- Flebogamma Dif
- Flo-pred
- fludrocortisone
- fosphenytoin
- Gamastan S/d
- Gammagard Liquid
- Gammagard S-d (iga < 1 Mcg/ml)
- Gammagard S/d
- Gammaked
- Gammaplex
- Gamunex-c
- Grx Hicort 25
- Hemril-30
- Hizentra
- hydrocortisone
- hydrocortisone acetate
- hydrocortisone sod succ (PF)
- hydrocortisone sod succinate
- immune glob(IgG)(hum)-maltose
- immune globulin (human) (IgG)
- immune globulin(hum),capr(IgG)
- Juxtapid
- Kenalog
- lomitapide
- Luminal
- Margesic
- Marten-tab
- Medrol
- Medrol (pak)
- methohexital
- methylprednisolone
- methylprednisolone acetate
- methylprednisolone sod suc(PF)
- methylprednisolone sodium succ
- methylprednisolone-bupivacaine
- Millipred
- Millipred Dp
- Mysoline
- Nembutal Sodium
- nystatin-hydrocortisone-diphen
- nystatin-TCN-HC-diphenhydramin
- Octagam
- Orapred
- Orapred Odt
- Pediapred
- Peganone
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Physicians Ez Use M-pred
- prednisolone
- prednisolone acetate
- prednisolone sodium phosphate
- prednisone
- Prednisone Intensol
- primidone
- Privigen
- Proctocort
- raloxifene
- Rayos
- Rectacort-hc
- secobarbital sodium
- Seconal Sodium
- Solu-cortef
- Solu-cortef (pf)
- Solu-medrol
- Solu-medrol (pf)
- Tencon
- triamcinolone acetonide
- triamcinolone hexacetonide
- triamcinolone-lidocaine
- Uceris
- Veripred 20
- Zebutal
- Acute myocardial infarction
- Antithrombin III deficiency
- Carcinoma of breast
- Cerebrovascular accident
- Deep venous thrombosis
- Disease of liver
- Estrogen-dependent neoplasm
- Lactating mother
- Malignant tumor of male breast
- Predisposition to thrombosis
- Pregnancy
- Prostatic carcinoma
- Protein C deficiency disease
- Pulmonary thromboembolism
- Thromboembolic disorder
- Thrombophilia
Contraindicated
- Acute myocardial infarction
- Bed-ridden
- Benign prostatic hyperplasia
- Cerebrovascular accident
- Coronary artery disease
- Dementia
- Disease of liver
- Endometrial carcinoma
- Family history of malignant tumor of breast
- Heart failure
- Hereditary angioedema
- Hypercalcemia
- Increased cardiovascular event risk
- Invasive surgical procedure
- Malignant neoplasm of the ovary
- Papilledema
- Retinal thrombosis
- Tobacco smoker
Severe
Moderate
- Asthma
- Diabetes mellitus
- Edema
- Gallbladder disease
- Hepatic porphyria
- Hypertriglyceridemia
- Hypoparathyroidism
- Hypothyroidism
- Kidney disease with reduction in GFR
- Migraine
- Neoplasm of liver
- Seizure disorder
- Systemic lupus erythematosus
- Unspecified lump in breast
- Uterine leiomyoma
ESTROGEN-METHYLTESTOSTERONE (ESTROGENS,ESTERIFIED/METHYLTESTOSTERONE)
- Amenorrhea
- Bladder irritability
- Gynecomastia
- Irregular menstrual periods
- Mastalgia
- Priapism
- Urinary tract infection
- Virilism
- Abdominal distension
- Abdominal pain with cramps
- Anorexia
- Breast milk flow decreased
- Dysmenorrhea
- Gynecomastia
- Mastalgia
- Nausea
- Peripheral edema
- Sinusitis
- Vulvovaginal candidiasis
- Weight gain
More Frequent
Severe
Less Severe
- Benign prostatic hyperplasia
- Disease of liver
- Dizziness
- Edema
- Endometrial hyperplasia
- Epididymitis
- Fatigue
- Flushing
- Gastroenteritis
- Headache disorder
- Hypercalcemia
- Hypertension
- Nausea
- Prostatic carcinoma
- Vomiting
- Acne vulgaris
- Bronchitis
- Diarrhea
- Dizziness
- Erectile dysfunction
- Headache disorder
- Increased pubic hair
- Insomnia
- Libido changes
- Migraine
- Mood changes
- Testicular atrophy
- Vaginal discharge
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Cerebrovascular accident
- Change in corneal curvature
- Deep venous thrombosis
- Drug-induced hepatitis
- Endometrial carcinoma
- Erythrocytosis
- Gallbladder obstruction
- Heart failure
- Hepatic necrosis
- Hepatitis
- Hypertension
- Influenza
- Involuntary muscle movement
- Leukopenia
- Malignant neoplasm of liver
- Malignant neoplasm of the ovary
- Neoplasm of breast
- Peliosis hepatis
- Pulmonary thromboembolism
- Retinal thrombosis
- Thromboembolic disorder
- Thrombotic disorder
- Unspecified lump in breast
- Urticaria
- Venous thrombosis
Less Severe
- Abnormal vaginal bleeding
- Aggressive behavior
- Amenorrhea
- Anorexia
- Back pain
- Body fluid retention
- Chest pain
- Depression
- Hostility
- Irritability
- Menorrhagia
- Nipple discharge
- Oligospermia
- Upper respiratory infection
Contraindicated
None
Severe Precaution
Methyltestosterone
May cause premature epiphyseal closure.
- 1 Day – 18 Years
- May cause premature epiphyseal closure.
Management or Monitoring Precaution
Estrogens, Esterified
Safety and efficacy in children has not been established.
- 1 Day – 13 Years
- Safety and efficacy in children has not been established.
Estrogenic Agents
- Severity Level:
2
- Additional Notes: Not indicated during pregnancy, no known dev tox
Methyltestosterone
- Severity Level:
X
- Additional Notes:
Contraindicated
Methyltestosterone
Poss sev adv effects,premature epiphyseal closure,virilization of females
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Poss sev adv effects,premature epiphyseal closure,virilization of females |
Precaution Exists
Estrogens,esterified
May decrease quantity and quality of breastmilk.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | May decrease quantity and quality of breastmilk. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Estrogenic Agents (systemic)
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
General-Avoid use in the elderly unless indicated for moderate to severe hypogonadism. Safer alternatives available. Urogenital-Risks for prostatic hypertrophy or carcinoma in men. Cardiovascular-Reports of venous thromboembolism, deep vein thrombosis and pulmonary embolism.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Methyltestosterone
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
General-Avoid use in the elderly unless indicated for moderate to severe hypogonadism. Safer alternatives available. Urogenital-Risks for prostatic hypertrophy or carcinoma in men. Cardiovascular-Reports of venous thromboembolism, deep vein thrombosis and pulmonary embolism.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- Estrogens given alone and with another hormone (progestin) for replacement therapy after menopause have sometimes caused rare but very serious side effects. Discuss the risks and benefits of hormone treatment and your personal health history with your doctor. Estrogens have been reported to increase the chance of cancer of the uterus (endometrial cancer).<br /><br />Taking a progestin with estrogen decreases this risk. Tell your doctor right away if you have any unusual vaginal bleeding. Estrogens may also increase your risk of cancer of the ovaries, stroke, dementia, and serious blood clots in the legs.<br /><br /> Estrogen given in combination with progestin can rarely cause heart disease (e.g., heart attacks), stroke, serious blood clots (pulmonary embolism and deep venous thrombosis), dementia, and cancer of the breast. Some of these risks appear to depend on the length of time this drug is used and the amount of estrogen per dose. Therefore, this medication should be used for the shortest possible length of time at the lowest effective dose, so you can obtain the benefits and reduce the chance of serious side effects from long-term treatment.<br /><br />Discuss the details with your doctor and check with him/her regularly (e.g., every 3 to 6 months) to see if you still need to take this medication. Estrogen treatment alone does not appear to increase your risk of breast cancer when used for up to 7 years after menopause. However, talk to your doctor about the risks if you need to take estrogen for a longer period.<br /><br /> Products that contain estrogen should not be used to prevent heart disease or dementia. If you use this drug for an extended period, you should have a complete physical exam at regular intervals (e.g., once a year) or as directed by your doctor. See Notes section.
Formulary Reference Tool